Drug Trial Radar · NCT04053387
Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)
Last checked: Nov 20, 2026Latest source record: Aug 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
763
Actual
Start
Aug 13, 2019
Primary completion
Apr 6, 2021
Study completion Apr 6, 2021
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- Collaborators
- IQVIA Biotech
- First posted
- Aug 12, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a long-term, open-label, multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in adults with plaque psoriasis. Subjects in this study completed treatment in 1 of 2 Phase 3 pivotal efficacy and safety studies (Study DMVT-505-3001 or Study DMVT-505-3002). This study will consist of up to 40 weeks of treatment and a 4-week safety follow-up period.
Conditions
- Plaque Psoriasis
Interventions
tapinarof cream, 1%Drug
Intermittent use of Tapinarof cream, 1%, applied once daily according to PGA score
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Adverse Events and Serious Adverse EventsTime frame: Baseline to 44 weeks
- Frequency of Adverse Events and Serious Adverse EventsTime frame: Baseline to 44 weeks
- Number of Subjects With Clinically Meaningful Changes From Baseline in Clinical Laboratory Values and Vital SignsTime frame: Baseline to 40 weeks
- Remittive Effect of Treatment Success in Pivotal: Median Time to First Worsening (PGA ≥ 2) While Off Therapy for Subjects Who Entered LTE PGA = 0 (Clear)Time frame: Baseline to 44 weeks
- Complete Disease Clearance During LTE: Number of Subjects Achieving Disease Clearance PGA =0 (Clear) While on Therapy for Subjects Entered LTE PGA ≥ 1 (Almost Clear)Time frame: Baseline to 44 weeks
- Response During LTE: Number of Subjects Achieving PGA =0 or 1 (Clear or Almost Clear) While on Therapy for Subjects Who Entered LTE With PGA ≥ 2 (Mild)Time frame: Baseline to 44 weeks
- Remittive Effect of Treatment Success: Number of Subjects Experiencing Worsening (PGA ≥ 2) While Off Therapy for Subjects Who Entered LTE With a PGA = 0 (Clear)Time frame: Baseline to 44 weeks
- Change From Baseline in %BSA AffectedTime frame: Baseline to 40 weeks
- Percent Change From Baseline in %BSA AffectedTime frame: Baseline to 40 weeks
- Mean Duration (Days) of Treatment CourseTime frame: Baseline to 40 weeks
- Change From Baseline in Psoriasis Area and Severity Index (PASI) ScoreTime frame: Baseline to 40 weeks
- Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) ScoreTime frame: Baseline to 40 weeks
- Change From Baseline in Disease Impact on Daily Activities, as Measured by the Dermatology Life Quality Index (DLQI)Time frame: Baseline to 40 weeks
- Percent Change From Baseline in Disease Impact on Daily Activities, as Measured by the Dermatology Life Quality Index (DLQI)Time frame: Baseline to 40 weeks
Locations
104 sites in 2 countries. Site status is shown where the registry gives one.
Dermavant Investigative Site
Birmingham, Alabama
Dermavant Investigative Site
Phoenix, Arizona
Dermavant Investigative Site
Bryant, Arkansas
Dermavant Investigative Site
Fort Smith, Arkansas
Dermavant Investigative Site
Fountain Valley, California
Dermavant Investigative Site
Fremont, California
Dermavant Investigative Site
Fresno, California
Dermavant Investigative Site
Los Angeles, California
Dermavant Investigative Site
Los Angeles, California
Dermavant Investigative Site
Northridge, California
Dermavant Investigative Site
Oceanside, California
Dermavant Investigative Site
San Diego, California
Dermavant Investigative Site
Santa Ana, California
Dermavant Investigative Site
Santa Monica, California
Dermavant Investigative Site
Denver, Colorado
Dermavant Investigative Site
Cromwell, Connecticut
Dermavant Investigative Site
Boca Raton, Florida
Dermavant Investigative Site
Boynton Beach, Florida
Dermavant Investigative Site
Hialeah, Florida
Dermavant Investigative Site
Margate, Florida
Dermavant Investigative Site
Miami, Florida
Dermavant Investigative Site
Miramar, Florida
Dermavant Investigative Site
Boise, Idaho
Dermavant Investigative Site
Rolling Meadows, Illinois
Dermavant Investigative Site
Evansville, Indiana
Dermavant Investigative Site
Indianapolis, Indiana
Dermavant Investigative Site
New Albany, Indiana
Dermavant Investigative Site
Plainfield, Indiana
Dermavant Investigative Site
Overland Park, Kansas
Dermavant Investigative Site
Louisville, Kentucky
Dermavant Investigative Site
Owensboro, Kentucky
Dermavant Investigative Site
Baton Rouge, Louisiana
Dermavant Investigative Site
New Orleans, Louisiana
Dermavant Investigative Site
Rockville, Maryland
Dermavant Investigative Site
Boston, Massachusetts
Dermavant Investigative Site
Bay City, Michigan
Dermavant Investigative Site
Clarkston, Michigan
Dermavant Clinical Site
Detroit, Michigan
Dermavant Investigational Site
Detroit, Michigan
Dermavant Investigative Site
Fort Gratiot, Michigan
Showing 40 of 104 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.